252 related articles for article (PubMed ID: 34282760)
1. Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
Lionetti M; Da Vià MC; Albano F; Neri A; Bolli N; Musto P
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282760
[TBL] [Abstract][Full Text] [Related]
2. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O
JAMA Oncol; 2020 Mar; 6(3):425-432. PubMed ID: 31830214
[TBL] [Abstract][Full Text] [Related]
3. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
4. Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma.
Manzoni M; Marchica V; Storti P; Ziccheddu B; Sammarelli G; Todaro G; Pelizzoni F; Salerio S; Notarfranchi L; Pompa A; Baldini L; Bolli N; Neri A; Giuliani N; Lionetti M
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456143
[TBL] [Abstract][Full Text] [Related]
5. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
Chojnacka M; Diamond B; Landgren O; Maura F
Semin Oncol; 2022 Feb; 49(1):11-18. PubMed ID: 35168813
[TBL] [Abstract][Full Text] [Related]
6. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
[TBL] [Abstract][Full Text] [Related]
7. Clonal Evolution of Multiple Myeloma-Clinical and Diagnostic Implications.
Salomon-Perzyński A; Jamroziak K; Głodkowska-Mrówka E
Diagnostics (Basel); 2021 Aug; 11(9):. PubMed ID: 34573876
[TBL] [Abstract][Full Text] [Related]
8. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
9. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Management of Smoldering Multiple Myeloma.
Madhira BR; Konala VM; Adapa S; Naramala S; Ravella PM; Parikh K; Gentile TC
World J Oncol; 2020 Apr; 11(2):45-54. PubMed ID: 32284772
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
12. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
Sundararajan S; Kumar A; Korde N; Agarwal A
Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
[TBL] [Abstract][Full Text] [Related]
13. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
14. Understanding high-risk smoldering multiple myeloma.
Kreiniz N; Gertz MA
Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
[TBL] [Abstract][Full Text] [Related]
15. Smoldering multiple myeloma.
Rajkumar SV; Landgren O; Mateos MV
Blood; 2015 May; 125(20):3069-75. PubMed ID: 25838344
[TBL] [Abstract][Full Text] [Related]
16. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
Korde N; Kristinsson SY; Landgren O
Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
[TBL] [Abstract][Full Text] [Related]
18. SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.
Schmidt T; Gahvari Z; Callander NS
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38641486
[TBL] [Abstract][Full Text] [Related]
19. Smoldering multiple myeloma 40 years later: a story of unintended disease.
Yavorkovsky LL
Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
[No Abstract] [Full Text] [Related]
20. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.
Calcinotto A; Ponzoni M; Ria R; Grioni M; Cattaneo E; Villa I; Sabrina Bertilaccio MT; Chesi M; Rubinacci A; Tonon G; Bergsagel PL; Vacca A; Bellone M
Oncoimmunology; 2015 Jun; 4(6):e1008850. PubMed ID: 26155424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
